Universal Cells
Universal Cells was established to commercialize gene-editing, stem cell engineering and immune rejection technologies for the treatment of human diseases. We are a Seattle-based company that creates engineered, allogeneic stem cells that can be differentiated into many types of therapeutic cells. Universal Cells is a Seattle-based company that is producing engineered stem cell lines that can avoid rejection and be used in allogeneic cell therapy treatments for the people who need them. Noboru Yamaji is the President and Chief Intelligence and Liaison Officer of Universal Cells. Kim Clary is the Executive Director, Clinical Gene Editing & Strategy at Universal Cells. Gary Dos Santos joined Universal Cells in the spring of 2023 as the Director of Facilities and Operations. Kyle Knobloch joined Universal Cells in 2023, bringing over 17 years of experience in Project, Program, and Alliance Management across diverse therapeutic areas and modalities. Most importantly, Kyle is passionate about advancing science with curative-intent from the bench to the clinic, for only then can patients be served.
This company is:
Verified
Technology | Universal Cells
Our Technology | Recombinant Adeno-Associated Virus | Editing the genome without breaking it | rAAV cassette | No Off-target Cutting | No On Target Mistakes | Non-toxic Delivery | No Nuclease Proteins | Pluripotent Stem Cells (PSCs) | Cells for every organ | Universal Donor Cells | OUR GOAL One cell for everyone No immune suppression. No donor matching. No rejection. | HLA Engineering | Total Control of Antigen Presentation | HLA Class I | HLA class II engineering | Selected Publications | Russell, D.W., and Hirata, R.K. (1998). Human gene targeting by viral vectors. Nature Genetics 18, 325-330. | Rutledge, E.A., Halbert, C.L., and Russell, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. Journal of Virology 72, 309-319. | Thomson, J.A., Itskovitz-Eldor, J., Shapiro, S.S., Waknitz, M.A., Swiergiel, J.J., Marshall, V.S., and Jones, J.M. (1998). Embryonic stem cell lines derived from human blastocysts. Science 282, 1145-1147. | Inoue, N., Hirata, R.K., and Russell, D.W. (1999). High-fidelity correction of mutations at multiple chromosomal positions by adeno-associated virus vectors. Journal of Virology 73, 7376-7380. | Inoue, N., Dong, R., Hirata, R.K., and Russell, D.W. (2001). Introduction of single base substitutions at homologous chromosomal sequences by adeno-associated virus vectors. Mol Ther. 3, 526-530. | Hirata, R., Chamberlain, J., Dong, R., and Russell, D.W. (2002). Targeted transgene insertion into human chromosomes by adeno-associated virus vectors. Nat Biotechnol 20, 735-738. | Chamberlain, J.R., Schwarze, U., Wang, P., Hirata, R.K., Hankenson, K.D., Pace, J.M., Underwood, R.A., Song, K.M., Sussman, M., Byers, P.H., et al. (2004). Gene targeting in stem cells from individuals with osteogenesis imperfecta. Mol Ther. 2008 Jan; 16(1): 187–193. | Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., and Yamanaka, S. (2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131, 861-872. | Yu, J., Vodyanik, M.A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J.L., Tian, S., Nie, J., Jonsdottir, G.A., Ruotti, V., Stewart, R., et al. (2007). Induced pluripotent stem cell lines derived from human somatic cells. Science 318, 1917-1920. | Mitsui, K., Suzuki, K., Aizawa, E., Kawase, E., Suemori, H., Nakatsuji, N., and Mitani, K. (2009). Gene targeting in human pluripotent stem cells with adeno-associated virus vectors. Biochem Biophys Res Commun 388, 711-717. | Khan, I.F., Hirata, R.K., Wang, P.R., Li, Y., Kho, J., Nelson, A., Huo, Y., Zavaljevski, M., Ware, C., and Russell, D.W. (2010). Engineering of human pluripotent stem cells by AAV-mediated gene targeting. Mol Ther 18, 1192-1199. | Deyle, D.R., Khan, I.F., Ren, G., Wang, P.R., Kho, J., Schwarze, U., and Russell, D.W. (2012). Normal Collagen and Bone Production by Gene-targeted Human Osteogenesis Imperfecta iPSCs. Mol Ther 20, 204-213. | Li, L.B., Chang, K.H., Wang, P.R., Hirata, R.K., Papayannopoulou, T., and Russell, D.W. (2012). Trisomy correction in Down syndrome induced pluripotent stem cells. Cell Stem Cell 11, 615-619. | Riolobos, L., Hirata, R.K., Turtle, C.J., Wang, P.R., Gornalusse, G.G., Zavajlevski, M., Riddell, S.R., and Russell, D.W. (2013). HLA engineering of human pluripotent stem cells. Mol Ther 21, 1232-1241. | Deyle, D.R., Hansen, R.S., Cornea, A.M., Li, L.B., Burt, A.A., Alexander, I.E., Sandstrom, R.S., Stamatoyannopoulos, J.A., Wei, C.L., and Russell, D.W. (2014). A genome-wide map of adeno-associated virus-mediated human gene targeting. Nat Struct Mol Biol 21, 969-975. | Gornalusse, G.G., Hirata, R.K., Funk, S.E., Riolobos, L., Lopes, V.S., Manske, G., Prunkard, D., Colunga, A.G., Hanafi, L.A., Clegg, D.O., et al. (2017). HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells. Nat Biotechnol 35, 765-772.
View all products
Keywords
Industries
Where is Universal Cells Inc. located?
The company Universal Cells Inc. is located in Seattle, Washington, United States. It's worth noting that the company may has more corporate locations
How many employees does Universal Cells Inc. approximately have?
As of the latest available information Universal Cells Inc. has around 11-50 employees worldwide.
When was Universal Cells Inc. founded?
Universal Cells Inc. was founded in 2013
In which industries does Universal Cells Inc. mainly work?
The company Universal Cells Inc. has it's main focus in the industries of Professional Services, Science and Engineering, Biotechnology, Health Care
Celularity
United States
101-250 Employees
2017
Cellistic
Belgium
11-50 Employees
Cells for Cells S.A.
Chile
11-50 Employees
2010
Shoreline Biosciences
United States
11-50 Employees
2020
Celloram Inc.
United States
11-50 Employees
2018
REGROW BIOSCIENCES
India
251-500 Employees
2009
Univercells
Belgium
11-50 Employees
2013
PrimeGen US
United States
11-50 Employees
2002
Topics which have been searched by others and may be interesting for you: